Supplemental Material:

Supplemental Table 1 – Buffer composition for CCV isolation protocol

Supplemental Table 2 – Podocyte CCV LC-MS results and comparison to the published

HeLa cell CCV proteome

Supplemental Figure 1 - Validation of enriched DTR-podocytes


Supplemental Table 1. Buffer composition for CCV isolation protocol. Composition

of Buffer A 10x, 1x, protease inhibitor cocktail, and D₂O sucrose solution.

Solution	Chemicals	Amount
Buffer A 10x	 2-(N-morpholino)ethanesulfonic acid (MES; 1M final) 	 19.52 g (1M final)
	 Ethylene glycol bis(β- aminoethylether)-N,N,N',N'- tetraacetic acid (EGTA) (200 mM) 	 5 ml (10 mM final)
	 MgCl₂ (2 M) 	 0.25 ml (5 mM final)
	 NaOH (10 M) dH₂O 	 Adjust to pH 6.5 Start with 80 ml, add to 100 ml total
Buffer A 1x	 Buffer A 10x NaOH (1 M) dH₂O 	 50 ml Adjust to pH 6.5 Start with 400 ml, add to 500 ml total
complete protease inhibitor cocktail 25x	complete (Roche)ddH₂O	1 tablet2 ml
D ₂ O-sucrose solution	 D₂O Sucrose Buffer A 10x 	 Start with 5 ml, add to 10 ml total 0.8 g (8% w/v final) 1ml

Supplemental Table 2. Podocyte CCV LC-MS results and comparison to the published HeLa cell CCV proteome. Sheet 1: Raw LC-MS readout of the podocyte CCV fraction ranked by Mascot score. Sheet 2: Top 520 proteins ranked by emPAI. Sheet 3: MS Dataset of HeLa cell CCVs from Borner et al.(15). Sheet 4: Proteins in podocyte CCVs not mentioned in HeLa dataset. Sheet 5: Proteins mentioned in both datasets. Sheet 6: Proteins mentioned in both datasets with a control/mock ratio of >1.46. Sheet 7: Overview over 36 survivors.

Supplemental Figure 1. Validation of enriched DTR-podocytes. (A) qPCR of genes of interest (GOI) for nephrin, WT1, and GAPDH in DTR podocytes and whole kidney lysates. (B) Representative immunoblots of nephrin, desmin, ve-cadherin, WT1, and GAPDH.



Supplemental Figure 1